Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

fludarabine 52Cyclophosphamide 50venetoclax 47Azacitidine 44fludarabine phosphate 41Whole-Body Irradiation 33Specimen Handling 31Mycophenolic Acid 30Tacrolimus 28Melphalan 28Busulfan 27Cytarabine 25Stem Cell Transplantation 23Decitabine 23Biopsy 22Granulocyte Colony-Stimulating Factor 19Sirolimus 16Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Thiotepa 15decitabine and cedazuridine drug combination 14Injections 13Cyclosporine 13ruxolitinib 9Methotrexate 9Mesna 9Hematopoietic Stem Cell Transplantation 9X-Rays 8Idarubicin 8Daunorubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × INCB059872 × 1 year × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡